A Phase 2 interventional study of ITF2357 in Active Systemic and Onset Juvenile Idiopathic Arthritis, sponsored by Italfarmaco. Completed at 5 sites in 2 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2021-05-04.
Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study has the following objectives:
Primary objective:
Secondary objectives:
The present study has been designed in order to evaluate safety and tolerability of ITF2357 in patients with active SOJIA with inadequate response or intolerance to standard therapy with oral steroids and methotrexate, with or without previously used biologic agents, and to have a preliminary evaluation of efficacy of ITF2357 in the treatment of SOJIA.
ITF2357 will be administered orally at the daily cumulative dose of 1.5 mg/kg: this dose in children/young adults is considered roughly equivalent to the dose of 1 mg/kg/day in adults, which so far has been proven to be free of any relevant safety concerns both in healthy volunteers and in patients.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
This study's enrollment of 17 is below the median of 52 across 230 interventional studies indexed under Arthritis, Juvenile.
Browse Arthritis, Juvenile studies →Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active disease for at least one month prior to enrolment as defined by the following criteria:
Presence of arthritis plus at least one of the following:
Previous treatment with biologics, if any, during at least three months without satisfactory effect or with drug intolerability, discontinued for at least the period specified below before patient's enrolment:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength (dose strengths of 7.5, 10, 12.5, 15, 20 mg and 50 mg). Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity
Drug: ITF2357
ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
Also known as: Givinostat, histone deacetylase inhibitor
Number of Patients Completing Week 12 of Treatment
The primary endpoint describes the number of patients who has completed week 12 of treatment with ITF2357, both in the Per protocol (PP) population and in the Intention to treat (ITT) population. ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength. Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity.
Time frame: At week 12
JIA Outcome Core Set Variables - Patient Global Assessment
Patient/parent global Visual Analogue Scale (VAS) is from 0 to 100. The lower the score, the better the outcome.
Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
JIA Outcome Core Set Variables - Physician Global Assessment
Physician global Visual Analogue Scale (VAS) is from 0 to 100. The lower the score, the better the outcome.
Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
JIA Outcome Core Set Variables - Number of Joints With Active Arthritis
Number of active joints is from 0 to 75. The lower the score, the better the outcome.
Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
JIA Outcome Core Set Variables - Number of Joints With Limitation
Number of joints with limited range of motion is from 0 to 75. The lower the score, the better the outcome.
Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
JIA Outcome Core Set Variables - CHAQ
The Childhood Health Assessment Questionnaire (CHAQ) is from 0 to 3. For each of 8 section (Dressing and care, Getting up, Eating, Walking, Hygiene, Grasping, Catching, Activities) answers patient is getting 0,1,2 or 3 points (no difficulties, some difficulties, much difficulties, unable to do, respectively). The sum of points is then divided by 8 to get score 0 - 3. The lower the score, the better the outcome.
Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
JIA Outcome Core Set Variables - ESR
Measurements of erythrocyte sedimentation rate (ESR) were performed at the local laboratory cooperating with each study site.
Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month and 3 months follow up (FU1, FU3) in the PP and ITT populations respectively.
Overall SFS Results - Sum of First Five Variables and Sum of Last Five Variables
Modified Systemic Feature Score (SFS) variables included: * temperature, rash, lymph nodes, liver and spleen size, and clinical evidence of serositis (clinical variables) * ESR, CRP, leukocyte count, haemoglobin, thrombocyte count (laboratory variables). Items in both sets of variables were scored as present (1) or not present (0) based on predefined criteria. SFS data were presented as the sum of the first 5 items and the sum of the last 5 items. Each sum could range from a minimum of 0 to a maximum of 5.
Time frame: At pretreatment visit, at weeks 2, 4, 6, 8, 10 and 12 (End of treatment), 1 month follow-up (FU1) in the PP and ITT populations respectively.
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Temperature
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Temperature was scored as present or not present according to the following criterion: body temperature ≥ 37.5 °C at least once a day during at least five consecutive days or presence of typical SOJIA intermittent temperature chart (patients' temperature chart analysis).
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Typical SOJIA Rash
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Typical SOJIA is a salmon pink rash on the trunk during the febrile episodes.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Lymphadenopathy
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Lymphadenopathy was scored as present or not present according to the following criterion: lymph node (nodes) enlargement to 1.5 cm or more, localized anywhere within the body.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Hepatomegaly and/or Splenomegaly
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Hepatomegaly and/or splenomegaly was scored as present if confirmed by ultrasound evaluation and established after comparison to age standards for organ size.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Serositis
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Serositis (pericarditis, pleuritis or peritonitis) was scored as present if confirmed by ultrasound and/or X-ray exploration or by the presence of typical ECG findings in the case of pericarditis.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Erythrocyte Sedimentation Rate (ESR)
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit ESR was scored as present or not present according to the following criterion: ESR considered as elevated if ≥ 20 mm/h (first hour) At the subsequent visits ESR was scored 0 (Not present) if decreased by at least 30% as compared to pre-treatment value or normalized (\< 20 mm/h); score 1 (Present) if increased or decreased less than 30%.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - C-reactive Protein (CRP)
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit CRP was scored as present or not present according to the following criterion: CRP considered as elevated if ≥ 10 mg/L. At the subsequent visits CRP was scored 0 (Not present) if decreased by at least 30% compared to pre-treatment value or normalized (\< 10 mg/L); score 1 (Present) if increased or decreased less than 30%.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - White Blood Cell (WBC)
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit WBC was scored as present or not present according to the following criterion: Leukocyte count considered as elevated if ≥ 12 x 103/μL. At the subsequent visits WBC was scored 0 (Not present) if decreased by 20% compared to pre-treatment value or normalized (\< 12x103/μL); score 1 (Present) if increased or decreased less than 20%.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Haemoglobin (Hb)
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit Hb was scored as present or not present according to the following criterion: Haemoglobin considered as lowered if below 11g/dL. At the subsequent visits Hb was scored 0 (Not present) if increased by 20% compared to pre-treatment value or normalized (\> 11 g/dL); score 1 (Present) if decreased or increased less than 20%.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With Presence or Absence of Each Item for Modified Systemic Feature Score (SFS) - Thrombocytes
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit thrombocyte count was scored as present or not present according to the following criterion: Thrombocyte count considered as increased if ≥ 400x103/μL. At the subsequent visits thrombocyte count was scored 0 (Not present) if decreased by 20% compared to pretreatment value or normalized (\< 400x103/μL); score 1 (Present) if increased or decreased less than 20%.
Time frame: Pre-treatment, Weeks 4, 8, 12, and 1-month follow up
Number of Patients With JIA Plus SFS Clinical Improvement
Clinical improvement at week 2, 4, 6, 8, 10 and 12 was evaluated on the basis of JIA30, JIA50 and JIA70 plus SFS (two points decrease in SFS) as per protocol. Patients were considered as improved and with positive therapeutic response if 3 or more JIA Core Set Variables improved by 30% and no more than one worsened by 30%. JIA50 and JIA70 were defined as an improvement of 3 or more JIA Core Set Variables by 50% and 70%, respectively, and no more than 1 worsened by 30%. Additionally two points decrease in Systemic Feature Score were considered as disease improvement.
Time frame: At weeks 2, 4, 6, 8, 10 and 12.
Number of Patients With Sufficient Therapeutic Response at Week 4 to Continue Treatment
Therapeutic response at week 4 was considered sufficient by the Investigator if a decrease in Systemic Feature Score of 2 (at least one of the first five variables) and/or JIA30 response (or above: 50 or 70) was obtained.
Time frame: At week 4
Seventeen patients were screened and enrolled in the study
| Milestone | ITF2357 |
|---|---|
| Started | 17 |
| Completed | 10 |
| Not completed | 7 |
| Withdrew: Disease worsening | 5 |
| Withdrew: Unmet criterion of sufficient therapeutic response | 1 |
| Withdrew: Adverse event | 1 |
The primary endpoint describes the number of patients who has completed week 12 of treatment with ITF2357, both in the Per protocol (PP) population and in the Intention to treat (ITT) population. ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength. Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity.
| Participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Completers | 9 | 10 |
| Non completers | 0 | 7 |
Patient/parent global Visual Analogue Scale (VAS) is from 0 to 100. The lower the score, the better the outcome.
| units on a scale | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Pre-treatment | 48.00 ± 22.50 | 47.71 ± 21.45 |
| Week 2 | 43.33 ± 21.15 | 42.47 ± 21.30 |
| Week 4 | 21.22 ± 14.00 | 28.88 ± 22.48 |
| Week 6 | 19.11 ± 15.00 | 22.36 ± 18.33 |
| Week 8 | 17.22 ± 14.59 | 18.00 ± 13.99 |
| Week 10 | 17.44 ± 13.28 | 22.33 ± 19.58 |
| Week 12 | 19.11 ± 14.57 | 24.21 ± 20.89 |
| FU1 | 18.11 ± 15.53 | 26.56 ± 18.02 |
| FU3 | 15.38 ± 15.32 | 22.71 ± 17.85 |
Physician global Visual Analogue Scale (VAS) is from 0 to 100. The lower the score, the better the outcome.
| units on a scale | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Pretreatment | 48.00 ± 22.50 | 47.71 ± 21.45 |
| Week 2 | 43.33 ± 21.15 | 42.47 ± 21.30 |
| Week 4 | 21.22 ± 14.00 | 28.88 ± 22.48 |
| Week 6 | 19.11 ± 15.00 | 22.36 ± 18.33 |
| Week 8 | 17.22 ± 14.59 | 18.00 ± 13.99 |
| Week 10 | 17.44 ± 13.28 | 22.33 ± 19.58 |
| Week 12 | 19.11 ± 14.57 | 24.21 ± 20.89 |
| FU1 | 18.11 ± 15.53 | 26.56 ± 18.02 |
| FU3 | 15.38 ± 15.32 | 22.71 ± 17.85 |
Number of active joints is from 0 to 75. The lower the score, the better the outcome.
| units on a scale | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Pretreatment | 9.33 ± 8.70 | 9.82 ± 9.11 |
| Week 2 | 7.11 ± 8.62 | 8.41 ± 9.49 |
| Week 4 | 3.78 ± 5.47 | 6.38 ± 9.26 |
| Week 6 | 3.44 ± 5.29 | 3.57 ± 4.33 |
| Week 8 | 3.67 ± 4.85 | 3.42 ± 4.29 |
| Week 10 | 2.89 ± 4.54 | 2.75 ± 4.03 |
| Week 12 | 3.44 ± 4.59 | 4.86 ± 4.74 |
| FU1 | 3.00 ± 4.50 | 3.88 ± 4.49 |
| FU3 | 3.33 ± 4.58 | 5.00 ± 6.05 |
Number of joints with limited range of motion is from 0 to 75. The lower the score, the better the outcome.
| units on a scale | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Pretreatment | 10.00 ± 9.53 | 11.59 ± 14.00 |
| Week 2 | 8.56 ± 9.76 | 10.41 ± 14.42 |
| Week 4 | 6.44 ± 7.20 | 7.44 ± 11.56 |
| Week 6 | 5.78 ± 7.17 | 7.86 ± 11.91 |
| Week 8 | 5.78 ± 6.63 | 4.67 ± 6.08 |
| Week 10 | 5.22 ± 6.32 | 4.42 ± 5.65 |
| Week 12 | 4.78 ± 5.65 | 8.79 ± 12.27 |
| FU1 | 5.00 ± 5.92 | 7.94 ± 12.22 |
| FU3 | 5.22 ± 5.70 | 7.20 ± 8.79 |
The Childhood Health Assessment Questionnaire (CHAQ) is from 0 to 3. For each of 8 section (Dressing and care, Getting up, Eating, Walking, Hygiene, Grasping, Catching, Activities) answers patient is getting 0,1,2 or 3 points (no difficulties, some difficulties, much difficulties, unable to do, respectively). The sum of points is then divided by 8 to get score 0 - 3. The lower the score, the better the outcome.
| units on a scale | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Pretreatment | 1.55 ± 0.54 | 1.75 ± 0.74 |
| Week 2 | 1.13 ± 0.57 | 1.39 ± 0.87 |
| Week 4 | 0.93 ± 0.55 | 1.23 ± 0.88 |
| Week 6 | 0.75 ± 0.56 | 1.02 ± 0.82 |
| Week 8 | 0.58 ± 0.50 | 0.85 ± 0.82 |
| Week 10 | 0.55 ± 0.50 | 0.85 ± 0.87 |
| Week 12 | 0.58 ± 0.41 | 0.95 ± 0.82 |
| FU1 | 0.56 ± 0.39 | 1.02 ± 0.93 |
| FU3 | 0.58 ± 0.51 | 0.85 ± 0.78 |
Measurements of erythrocyte sedimentation rate (ESR) were performed at the local laboratory cooperating with each study site.
| mm/hr | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Pretreatment | 65.22 ± 23.05 | 62.71 ± 31.76 |
| Week 2 | 53.44 ± 26.54 | 59.12 ± 30.90 |
| Week 4 | 52.67 ± 22.66 | 59.50 ± 34.71 |
| Week 6 | 57.67 ± 20.66 | 53.90 ± 22.35 |
| Week 8 | 49.33 ± 33.78 | 49.92 ± 31.20 |
| Week 10 | 58.33 ± 23.40 | 59.25 ± 23.35 |
| Week 12 | 56.44 ± 40.76 | 54.14 ± 37.07 |
| FU1 | 39.89 ± 28.32 | 46.31 ± 28.30 |
| FU3 | 44.57 ± 25.00 | 41.00 ± 25.02 |
Modified Systemic Feature Score (SFS) variables included: * temperature, rash, lymph nodes, liver and spleen size, and clinical evidence of serositis (clinical variables) * ESR, CRP, leukocyte count, haemoglobin, thrombocyte count (laboratory variables). Items in both sets of variables were scored as present (1) or not present (0) based on predefined criteria. SFS data were presented as the sum of the first 5 items and the sum of the last 5 items. Each sum could range from a minimum of 0 to a maximum of 5.
| score on a scale | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Sum of first 5 (clinical) variables - pre-treatment | 1.33 ± 0.71 | 0.94 ± 0.75 |
| Sum of first 5 (clinical) variables - Week 2 | 0.44 ± 0.73 | 0.35 ± 0.61 |
| Sum of first 5 (clinical) variables - Week 4 | 0.11 ± 0.33 | 0.31 ± 0.48 |
| Sum of first 5 (clinical) variables - Week 6 | 0.11 ± 0.33 | 0.14 ± 0.36 |
| Sum of first 5 (clinical) variables - Week 8 | 0.11 ± 0.33 | 0.17 ± 0.39 |
| Sum of first 5 (clinical) variables - Week 10 | 0.11 ± 0.33 | 0.33 ± 0.65 |
| Sum of first 5 (clinical) variables - Week 12 | 0.22 ± 0.44 | 0.29 ± 0.47 |
| Sum of first 5 (clinical) variables - FU1 | 0.22 ± 0.44 | 0.20 ± 0.41 |
| Sum of last 5 (lab) variables - pretreatment | 4.33 ± 1.00 | 4.24 ± 1.15 |
| Sum of last 5 (lab) variables - week 2 | 2.44 ± 1.42 | 2.65 ± 1.17 |
| Sum of last 5 (lab) variables - week 4 | 2.11 ± 0.93 | 2.25 ± 1.18 |
| Sum of last 5 (lab) variables - week 6 | 1.56 ± 1.33 | 1.93 ± 1.21 |
| Sum of last 5 (lab) variables - week 8 | 2.00 ± 1.66 | 1.92 ± 1.44 |
| Sum of last 5 (lab) variables - week 10 | 2.00 ± 1.58 | 2.08 ± 1.38 |
| Sum of last 5 (lab) variables - week 12 | 1.89 ± 1.45 | 2.07 ± 1.27 |
| Sum of last 5 (lab) variables - FU1 | 2.22 ± 1.92 | 2.56 ± 1.67 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Temperature was scored as present or not present according to the following criterion: body temperature ≥ 37.5 °C at least once a day during at least five consecutive days or presence of typical SOJIA intermittent temperature chart (patients' temperature chart analysis).
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Temp - Pretreatment - absence | 4 | 10 |
| Temp - Pretreatment - presence | 5 | 7 |
| Temp - Week 4 - absence | 8 | 12 |
| Temp - Week 4 - presence | 1 | 4 |
| Temp - Week 8 - absence | 8 | 10 |
| Temp - Week 8 - presence | 1 | 2 |
| Temp - Week 12 - absence | 7 | 11 |
| Temp - Week 12 - presence | 2 | 3 |
| Temp - FU1 - absence | 7 | 12 |
| Temp - FU1 - presence | 2 | 3 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Typical SOJIA is a salmon pink rash on the trunk during the febrile episodes.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Rash - Pretreatment - absence | 6 | 14 |
| Rash - Pretreatment - presence | 3 | 3 |
| Rash - Week 4 - absence | 9 | 16 |
| Rash - Week 4 - presence | 0 | 0 |
| Rash - Week 8 - absence | 9 | 12 |
| Rash - Week 8 - presence | 0 | 0 |
| Rash - Week 12 - absence | 9 | 14 |
| Rash - Week 12 - presence | 0 | 0 |
| Rash - FU1 - absence | 9 | 16 |
| Rash - FU1 - presence | 0 | 0 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Lymphadenopathy was scored as present or not present according to the following criterion: lymph node (nodes) enlargement to 1.5 cm or more, localized anywhere within the body.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Lymphadenopathy - Pretreatment - absence | 6 | 13 |
| Lymphadenopathy - Pretreatment - presence | 3 | 4 |
| Lymphadenopathy - Week 4 - absence | 9 | 16 |
| Lymphadenopathy - Week 4 - presence | 0 | 0 |
| Lymphadenopathy - Week 8 - absence | 9 | 12 |
| Lymphadenopathy - Week 8 - presence | 0 | 0 |
| Lymphadenopathy - Week 12 - absence | 9 | 14 |
| Lymphadenopathy - Week 12 - presence | 0 | 0 |
| Lymphadenopathy - FU1 - absence | 9 | 16 |
| Lymphadenopathy - FU1 - presence | 0 | 0 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Hepatomegaly and/or splenomegaly was scored as present if confirmed by ultrasound evaluation and established after comparison to age standards for organ size.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Hepatomegaly - Pretreatment - absence | 8 | 16 |
| Hepatomegaly - Pretreatment - presence | 1 | 1 |
| Hepatomegaly - Week 4 - absence | 9 | 16 |
| Hepatomegaly - Week 4 - presence | 0 | 0 |
| Hepatomegaly - Week 8 - absence | 9 | 12 |
| Hepatomegaly - Week 8 - presence | 0 | 0 |
| Hepatomegaly - Week 12 - absence | 9 | 14 |
| Hepatomegaly - Week 12 - presence | 0 | 0 |
| Hepatomegaly - FU1 - absence | 9 | 16 |
| Hepatomegaly - FU1 - presence | 0 | 0 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count Serositis (pericarditis, pleuritis or peritonitis) was scored as present if confirmed by ultrasound and/or X-ray exploration or by the presence of typical ECG findings in the case of pericarditis.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Serositis - Pretreatment - absence | 9 | 16 |
| Serositis - Pretreatment - presence | 0 | 1 |
| Serositis - Week 4 - absence | 9 | 15 |
| Serositis - Week 4 - presence | 0 | 1 |
| Serositis - Week 8 - absence | 9 | 12 |
| Serositis - Week 8 - presence | 0 | 0 |
| Serositis - Week 12 - absence | 9 | 13 |
| Serositis - Week 12 - presence | 0 | 1 |
| Serositis - FU1 - absence | 9 | 16 |
| Serositis - FU1 - presence | 0 | 0 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit ESR was scored as present or not present according to the following criterion: ESR considered as elevated if ≥ 20 mm/h (first hour) At the subsequent visits ESR was scored 0 (Not present) if decreased by at least 30% as compared to pre-treatment value or normalized (\< 20 mm/h); score 1 (Present) if increased or decreased less than 30%.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| ESR - Pretreatment - absence | 0 | 1 |
| ESR - Pretreatment - presence | 9 | 16 |
| ESR - Week 4 - absence | 2 | 5 |
| ESR - Week 4 - presence | 7 | 11 |
| ESR - Week 8 - absence | 4 | 4 |
| ESR - Week 8 - presence | 5 | 8 |
| ESR - Week 12 - absence | 3 | 5 |
| ESR - Week 12 - presence | 6 | 9 |
| ESR - FU1 - absence | 4 | 6 |
| ESR - FU1 - presence | 5 | 10 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit CRP was scored as present or not present according to the following criterion: CRP considered as elevated if ≥ 10 mg/L. At the subsequent visits CRP was scored 0 (Not present) if decreased by at least 30% compared to pre-treatment value or normalized (\< 10 mg/L); score 1 (Present) if increased or decreased less than 30%.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| CRP - Pretreatment - absence | 0 | 0 |
| CRP - Pretreatment - presence | 9 | 17 |
| CRP - Week 4 - absence | 5 | 8 |
| CRP - Week 4 - presence | 4 | 8 |
| CRP - Week 8 - absence | 4 | 6 |
| CRP - Week 8 - presence | 5 | 6 |
| CRP - Week 12 - absence | 5 | 6 |
| CRP - Week 12 - presence | 4 | 8 |
| CRP - FU1 - absence | 6 | 10 |
| CRP - FU1 - presence | 3 | 6 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit WBC was scored as present or not present according to the following criterion: Leukocyte count considered as elevated if ≥ 12 x 103/μL. At the subsequent visits WBC was scored 0 (Not present) if decreased by 20% compared to pre-treatment value or normalized (\< 12x103/μL); score 1 (Present) if increased or decreased less than 20%.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| WBC - Pretreatment - absence | 2 | 4 |
| WBC - Pretreatment - presence | 7 | 13 |
| WBC - Week 4 - absence | 6 | 10 |
| WBC - Week 4 - presence | 3 | 6 |
| WBC - Week 8 - absence | 7 | 10 |
| WBC - Week 8 - presence | 2 | 2 |
| WBC - Week 12 - absence | 7 | 10 |
| WBC - Week 12 - presence | 2 | 4 |
| WBC - FU1 - absence | 5 | 6 |
| WBC - FU1 - presence | 4 | 10 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit Hb was scored as present or not present according to the following criterion: Haemoglobin considered as lowered if below 11g/dL. At the subsequent visits Hb was scored 0 (Not present) if increased by 20% compared to pre-treatment value or normalized (\> 11 g/dL); score 1 (Present) if decreased or increased less than 20%.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Hb - Pretreatment - absence | 3 | 6 |
| Hb - Pretreatment - presence | 6 | 11 |
| Hb - Week 4 - absence | 4 | 6 |
| Hb - Week 4 - presence | 5 | 10 |
| Hb - Week 8 - absence | 4 | 6 |
| Hb - Week 8 - presence | 5 | 6 |
| Hb - Week 12 - absence | 4 | 6 |
| WBC - Week 12 - presence | 5 | 8 |
| Hb - FU1 - absence | 4 | 8 |
| Hb - FU1 - presence | 5 | 8 |
SFS variables included: 1. temperature 2. rash 3. lymph nodes 4. liver and spleen size 5. clinical evidence of serositis (pericarditis, pleuritis or peritonitis) 6. ESR 7. CRP 8. leukocyte count 9. haemoglobin 10. thrombocyte count At the pre-treatment visit thrombocyte count was scored as present or not present according to the following criterion: Thrombocyte count considered as increased if ≥ 400x103/μL. At the subsequent visits thrombocyte count was scored 0 (Not present) if decreased by 20% compared to pretreatment value or normalized (\< 400x103/μL); score 1 (Present) if increased or decreased less than 20%.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Thrombocytes - Pretreatment - absence | 1 | 2 |
| Thrombocytes - Pretreatment - presence | 8 | 15 |
| Thrombocytes - Week 4 - absence | 9 | 15 |
| Thrombocytes - Week 4 - presence | 0 | 1 |
| Thrombocytes - Week 8 - absence | 8 | 11 |
| Thrombocytes - Week 8 - presence | 1 | 1 |
| Thrombocytes - Week 12 - absence | 9 | 14 |
| Thrombocytes - Week 12 - presence | 0 | 0 |
| Thrombocytes - FU1 - absence | 6 | 9 |
| Thrombocytes - FU1 - presence | 3 | 7 |
Clinical improvement at week 2, 4, 6, 8, 10 and 12 was evaluated on the basis of JIA30, JIA50 and JIA70 plus SFS (two points decrease in SFS) as per protocol. Patients were considered as improved and with positive therapeutic response if 3 or more JIA Core Set Variables improved by 30% and no more than one worsened by 30%. JIA50 and JIA70 were defined as an improvement of 3 or more JIA Core Set Variables by 50% and 70%, respectively, and no more than 1 worsened by 30%. Additionally two points decrease in Systemic Feature Score were considered as disease improvement.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| JIA30 plus SFS - W2 - Clinical improvement | 7 | 11 |
| JIA30 plus SFS - W2 - Absence of clinical improvement | 2 | 6 |
| JIA30 plus SFS - W4 - Clinical improvement | 8 | 12 |
| JIA30 plus SFS - W4 - Absence of clinical improvement | 1 | 5 |
| JIA30 plus SFS - W6 - Clinical improvement | 8 | 12 |
| JIA30 plus SFS - W6 - Absence of clinical improvement | 1 | 5 |
| JIA30 plus SFS - W8 - Clinical improvement | 8 | 11 |
| JIA30 plus SFS - W8 - Absence of clinical improvement | 1 | 6 |
| JIA30 plus SFS - W10 - Clinical improvement | 8 | 11 |
| JIA30 plus SFS - W10 - Absence of clinical improvement | 1 | 6 |
| JIA30 plus SFS - W12 - Clinical improvement | 8 | 10 |
| JIA30 plus SFS - W12 - Absence of clinical improvement | 1 | 7 |
| JIA50 plus SFS - W2 - Clinical improvement | 7 | 11 |
| JIA50 plus SFS - W2 - Absence of clinical improvement | 2 | 6 |
| JIA50 plus SFS - W4 - Clinical improvement | 8 | 10 |
| JIA50 plus SFS - W4 - Absence of clinical improvement | 1 | 7 |
| JIA50 plus SFS - W6 - Clinical improvement | 8 | 11 |
| JIA50 plus SFS - W6 - Absence of clinical improvement | 1 | 6 |
| JIA50 plus SFS - W8 - Clinical improvement | 8 | 10 |
| JIA50 plus SFS - W8 - Absence of clinical improvement | 1 | 7 |
| JIA50 plus SFS - W10 - Clinical improvement | 8 | 9 |
| JIA50 plus SFS - W10 - Absence of clinical improvement | 1 | 8 |
| JIA50 plus SFS - W12 - Clinical improvement | 8 | 9 |
| JIA50 plus SFS - W12 - Absence of clinical improvement | 1 | 8 |
| JIA70 plus SFS - W2 - Clinical improvement | 6 | 10 |
| JIA70 plus SFS - W2 - Absence of clinical improvement | 3 | 7 |
| JIA70 plus SFS - W4 - Clinical improvement | 8 | 10 |
| JIA70 plus SFS - W4 - Absence of clinical improvement | 1 | 7 |
| JIA70 plus SFS - W6 - Clinical improvement | 8 | 10 |
| JIA70 plus SFS - W6 - Absence of clinical improvement | 1 | 7 |
| JIA70 plus SFS - W8 - Clinical improvement | 8 | 9 |
| JIA70 plus SFS - W8 - Absence of clinical improvement | 1 | 8 |
| JIA70 plus SFS - W10 - Clinical improvement | 8 | 9 |
| JIA70 plus SFS - W10 - Absence of clinical improvement | 1 | 8 |
| JIA70 plus SFS - W12 - Clinical improvement | 8 | 9 |
| JIA70 plus SFS - W12 - Absence of clinical improvement | 1 | 8 |
Therapeutic response at week 4 was considered sufficient by the Investigator if a decrease in Systemic Feature Score of 2 (at least one of the first five variables) and/or JIA30 response (or above: 50 or 70) was obtained.
| participants | ITF2357 - PP Population | ITF2357 - ITT Population |
|---|---|---|
| Therapeutic response | 8 | 11 |
| Absence of therapeutic response | 1 | 6 |
Collected over At weeks 1, 2, 4, 6, 8, 10, 12 (end of treatment) and FU1 and FU3. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IT2357 - Safety Population | 0/17 (0%) | 2/17 (11.8%) | 14/17 (82.4%) |
| Event | IT2357 - Safety Population |
|---|---|
| VaricellaInfections and infestations | 1/17 |
| CellulitisInfections and infestations | 1/17 |
| Event | IT2357 - Safety Population |
|---|---|
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/17 |
| ArthritisMusculoskeletal and connective tissue disorders | 3/17 |
| RashSkin and subcutaneous tissue disorders | 2/17 |
| InfluenzaInfections and infestations | 2/17 |
| InjuryInjury, poisoning and procedural complications | 1/17 |
| Electrocardiogram QT prolongedInvestigations | 1/17 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 1/17 |
| FatigueGeneral disorders | 1/17 |
| PyrexiaGeneral disorders | 1/17 |
| DepressionPsychiatric disorders | 1/17 |
Safety population: all recruited patients who received at least one dose of the study medication.
| Age, Categorical(Participants) | ITF2357 |
|---|---|
| <=18 years | 15 |
| Between 18 and 65 years | 2 |
| >=65 years | 0 |
| Age, Continuous(years) | ITF2357 |
|---|---|
| Mean | 11.18 ± 5.39 |
| Sex: Female, Male(Participants) | ITF2357 |
|---|---|
| Female | 6 |
| Male | 11 |
| Region of Enrollment(participants) | ITF2357 |
|---|---|
| Romania | 5 |
| Serbia | 12 |
Ran from Sep 2006 to primary completion in Aug 2008, 23 months.
Results were first posted in May 2021, 12 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat